Eli Lilly and Company (NYSE:LLY) Shares Sold by KPP Advisory Services LLC

KPP Advisory Services LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 5.2% during the second quarter, Holdings Channel.com reports. The firm owned 2,862 shares of the company’s stock after selling 157 shares during the quarter. KPP Advisory Services LLC’s holdings in Eli Lilly and Company were worth $2,591,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Core Wealth Advisors Inc. increased its position in shares of Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares in the last quarter. Lynx Investment Advisory purchased a new position in Eli Lilly and Company during the 2nd quarter valued at about $32,000. LGT Financial Advisors LLC purchased a new position in Eli Lilly and Company during the 2nd quarter valued at about $36,000. Frank Rimerman Advisors LLC acquired a new position in Eli Lilly and Company during the fourth quarter worth about $37,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at about $40,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 0.9 %

NYSE LLY opened at $885.56 on Tuesday. The firm has a market capitalization of $841.64 billion, a price-to-earnings ratio of 130.42, a PEG ratio of 2.78 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a one year low of $516.57 and a one year high of $972.53. The company’s 50 day moving average price is $896.50 and its 200 day moving average price is $844.99.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. On average, sell-side analysts predict that Eli Lilly and Company will post 16.49 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on LLY shares. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Bank of America raised their price target on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $725.00 to $1,025.00 in a research report on Monday, August 12th. Finally, Jefferies Financial Group raised their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $977.35.

Insider Activity at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 52,369 shares of the firm’s stock in a transaction dated Friday, July 5th. The stock was sold at an average price of $915.18, for a total transaction of $47,927,061.42. Following the completion of the sale, the insider now directly owns 97,247,403 shares in the company, valued at $88,998,878,277.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders sold 364,810 shares of company stock valued at $339,366,198. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.